Inhibitory effects of sizofiran on anticancer agent- or X-ray-induced sister chromatid exchanges and mitotic block in murine bone marrow cells.
The inhibitory effects of a biological response modifier (BRM), sizofiran, on sister chromatid exchanges (SCEs) in the bone marrow cells of mice treated with various anticancer agents or irradiation were investigated. Sizofiran (10 mg/kg i.m.) inhibited SCEs induced by mitomycin C (2 mg/kg i.v.), adriamycin (20 mg/kg i.v.) and cyclophosphamide (20 mg/kg i.v.) by about 20%, respectively. Analysis of the SCEs in vivo after irradiation plus sizofiran indicated that SCE levels were significantly lower than those observed in mice exposed to irradiation without sizofiran. Moreover, the effects of sizofiran were dependent on the timing of administration. Our results indicated that sizofiran should be administered simultaneously or soon after irradiation in order to minimize damage. Sizofiran also markedly restored the bone marrow cell mitosis which had been suppressed by anticancer agents, and this action was closely correlated with the prevention of increase in SCEs. These results indicate that in addition to immunopotentiating activity, sizofiran may play a role in preventing chromosomal damage induced by cancer chemotherapy and radiotherapy.
Yang
Z B
ZB
Central Research Laboratories, Kaken Pharmaceutical Co. Ltd. Kyoto.
Tsuchiya
Y
Y
Arika
T
T
Hosokawa
M
M
D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D001853:Bone Marrow / Q000187:drug effects* / Q000528:radiation effects; D001854:Bone Marrow Cells; D002240:Carbohydrate Sequence; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D008940:Mitotic Index / Q000187:drug effects*; D008969:Molecular Sequence Data; D012854:Sister Chromatid Exchange / Q000187:drug effects* / Q000528:radiation effects; D012566:Sizofiran / Q000494:pharmacology*
D000970:Antineoplastic Agents; D012566:Sizofiran